AbbVie and Xilio Therapeutics have announced a partnership worth over $2.1bn to develop tumour-activated, antibody-based immunotherapies. The collaboration and option-to-licence agreement will include ...

ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

Learn More » AbbVie is recognized as a leading drugmaker with an extensive portfolio of therapeutics in fields such as immunology, oncology, neuroscience, and eye care. Additionally, the company ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...

AbbVie has secured its fourth FDA approval ... Also in the mix are new drugs, including Sage Therapeutics/Biogen's GABA A receptor modulator zuranolone – heading for an FDA decision next year ...

Roche Holding AG Akt-0.06% CHF238.35B ...